TACT2

Trial to Assess Chelation Therapy 2

ClinicalTrials.gov: NCT02733185

Patient Population:

  • 1,200 post-MI patients with diabetes
  • 50 yrs or older
  • History of diabetes and myocardial infarction

Trial Design: Double-blind, randomized

Intervention: EDTA chelation therapy versus placebo in individuals with coronary artery disease and diabetes

Primary Endpoint: A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina

Sponsors: NIH, NHLBI, NCCIH

Economic Substudy

Principal Investigator:

Daniel B. Mark, MD

TACT2: ECONOMIC STUDY

Overview

The specific aim of the economic substudy of the Trial to Assess Chelation Therapy 2 is to perform an economic analysis including a cost-effectiveness assessment of the TACT2 chelation strategy.

Trial is enrolling.

See study website for more information.

TACT2 Publications